NCT04811339View on ClinicalTrials.gov

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

August 15, 2021

Study Completion Date

August 15, 2021

Conditions
DiarrheaCOVID-19
Interventions
DRUG

Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable

Pepto bismol (bismuth subsalicylate)

OTHER

Placebo oral tablet without BSS

Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)

Trial Locations (1)

40202

University of Louisville, Louisville

All Listed Sponsors
collaborator

Procter and Gamble

INDUSTRY

lead

University of Cincinnati

OTHER

NCT04811339 - Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol) | Biotech Hunter | Biotech Hunter